Drug Trial Radar · NCT01341379
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate
Last checked: Nov 20, 2026Latest source record: May 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Dec 2010
Primary completion
Aug 2012
Study completion Aug 2012
Sponsor
- Lead sponsor
- Children's Hospital of PhiladelphiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- First posted
- Apr 25, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 3 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors of metabolism. The investigators propose to determine if short-term (3 day) treatment with N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients. The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators would consider more extensive long-term studies of the drug.
Conditions
- Urea Cycle Disorders, Inborn
- Inborn Errors of Metabolism
- Propionic Acidemia
- Methylmalonic Acidemia
- Carbamyl Phosphate Synthetase Deficiency
Interventions
N-carbamylglutamateDrug
N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of ureagenesisTime frame: 3 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.